WHAT IS CLAIMED IS:

1. A compound of formula (I)



(I),

or a pharmaceutically acceptable salt thereof, wherein:

A is



;

wherein:

 denotes the point of attachment to the carbonyl group and  denotes the point of attachment to the nitrogen atom;

n is 0 or 1;

R^{14} and R^{15} are independently selected from hydrogen and methyl; and

R^{16} is selected from hydrogen, $-CHR^{17}C(O)NH_2$, $-CHR^{17}C(O)NHCHR^{18}C(O)NH_2$, and $-CHR^{17}C(O)NHCHR^{18}C(O)NHCH_2C(O)NH_2$;

wherein R^{17} is selected from hydrogen and $-CH_2OH$ and wherein R^{18} is selected from hydrogen and methyl;

R^c, R^f, R^h, R^i, R^m, and R^n are hydrogen;

R^a, R^e, and R^j, are each independently selected from hydrogen and methyl;

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and R^{13} are independently selected from a natural amino acid side chain and an unnatural amino acid side chain or form a ring with the corresponding vicinal R group as described below;

R^e and R^k can each form a ring with the corresponding vicinal R group and the atoms to which they are attached selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy;

R^b is methyl or, R^b and R^2, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy;

R^d is methyl or, R^d and R^4, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halo, hydroxy, and phenyl;

R_g is methyl or, R^g and R^7, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, benzyl optionally substituted with a halo group, benzyloxy, cyano, cyclohexyl, methyl, halo, hydroxy, isoquinolinyloxy optionally substituted with a methoxy group, quinolinyloxy optionally substituted with a halo group, and tetrazolyl; and wherein the pyrrolidine and the piperidine ring are optionally fused to a cyclohexyl, phenyl, or indole group;

R^l is methyl or, R^l and R^{12}, together with the atoms to which they are attached, form a ring selected from azetidine and pyrollidine, wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy; and

R^k is methyl or, R^k and R^{11}, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halo, and hydroxy.

2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^d and R^4, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halo, and hydroxy;

R^g and R^7, together with the atoms to which they are attached, form a pyrollidine ring, wherein said ring is optionally substituted with one or two groups independently selected from amino, benzyl optionally substituted with a halo group, benzyloxy, cyano, cyclohexyl, methyl, halo, hydroxy, isoquinolinyloxy optionally substituted with a methoxy group, quinolinyloxy optionally substituted with a halo group, and tetrazolyl; and wherein the pyrrolidine and the piperidine ring are optionally fused to a cyclohexyl, phenyl, or indole group; and

R^k is methyl.

3. A compound of claim 2, or a therapeutically acceptable salt thereof, wherein R^8 is selected from

azaindolylC_1-C_3alkyl, benzothiazolylC_1-C_3alkyl, benzothienylC_1-C_3alkyl, benzyloxyC_1-C_3alkyl, diphenylmethyl, furanylC_1-C_3alkyl, imidazolylC_1-C_3alkyl, naphthylC_1-C_3alkyl, pyridinylC_1-C_3alkyl, thiazolylC_1-C_3alkyl, thienylC_1-C_3alkyl; and

indolylC_1-C_3alkyl, wherein the indolyl part is optionally substituted with one group selected from C_1-C_3alkyl, cyano, halo, and hydroxy.

4. A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R^8 is 3-indolylC_1-C_3alkyl optionally substituted with one group selected from C_1-C_3alkyl, halo, hydroxy, or cyano.

5. A compound selected from:

Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17, Compound 18, Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, Compound 24, Compound 25, Compound 26, Compound 27, Compound 28, Compound 29, Compound 30, Compound 31, Compound 32, Compound 33, Compound 34, Compound 35, Compound 36,

Compound 37, Compound 38, Compound 39, Compound 40, Compound 41, Compound 42, Compound 43, Compound 44, Compound 52, Compound 53, Compound 54, Compound 55, Compound 56, Compound 57, Compound 58, Compound 59, Compound 60, Compound 61, Compound 62, Compound 63, Compound 64, Compound 65, Compound 66, Compound 67, Compound 68, Compound 69, Compound 70, Compound 88, Compound 91, Compound 92, Compound 93, Compound 94, Example 1002, Example 1003, Example 1004, Example 1005, Example 1006, Example 1007, Example 1008, Example 1009, Example 1010, Example 1011, Example 1012, Example 1013, Example 1014, Example 1015, Example 1016, Example 1017, Example 1018, Example 1019, Example 1020, Example 1021, Example 1022, Example 1023, Example 1024, Example 1025, Example 1026, Example 1027, Example 1028, Example 1029, Example 1030, Example 1031, Example 1032, Example 1033, Example 1034, Example 1035, Example 1036, Example 1037, Example 1038, Example 1039, Example 1040, Example 1041, Example 1042, Example 1043, Example 1044, Example 1045, Example 1046, Example 1047, Example 1048, Example 1049, Example 1050, Example 1051, Example 1052, Example 1053, Example 1054, Example 1055, Example 1056, Example 1057, Example 1058, Example 1059, Example 1060, Example 1061, Example 1062, Example 1063, Example 1064, Example 1065, Example 1066, Example 1067, Example 1068, Example 1069, Example 1070, Example 1071, Example 1072, Example 1073, Example 1074, Example 1075, Example 1076, Example 1077, Example 1078, Example 1079, Example 1080, Example 1081, Example 1082, Example 1083, Example 1084, Example 1085, Example 1086, Example 1087, Example 1088, Example 1089, Example 1090, Example 1091, Example 1092, Example 1093, Example 1094, Example 1095, Example 1096, Example 1097, Example 1098, Example 1099, Example 1100, Example 1101, Example 1102, Example 1103, Example 1104, Example 1105, Example 1106, Example 1107, Example 1108, Example 1110, Example 1112, Example 1113, Example 1114, Example 1115, Example 1116, Example 1117, Example 1118, Example 1119, Example 1120, Example 1121, Example 1122, Example 1123, Example 1124, Example 1125, Example 1126, Example 1127, Example 1128, Example 1129, Example 1130, Example 1131, Example 1132, Example 1133, Example 1134, Example 1135, Example 1136, Example 1137, Example 1138, Example 1139, Example 1140, Example 1141, Example 1142, Example 1143, Example 1144, Example 1145, Example 1146, Example 1147, Example 1148, Example 1149, Example 1150, Example 1151, Example 1152, Example 1153, Example 1154, Example 1155, Example 1156, Example 1157, Example 1158, Example 1159, Example 1160, Example 1161, Example 1162, Example 1163, Example 1164, Example 1165, Example 1166, Example 1167, Example 1168, Example 1169,

Example 1170, Example 1171, Example 1172, Example 1173, Example 1174, Example 1175, Example 1176, Example 1177, Example 1178, Example 1179, Example 1180, Example 1181, Example 1182, Example 1183, Example 1184, Example 1185, Example 1186, Example 1187, Example 1188, Example 1189, Example 1190, Example 1191, Example 1192, Example 1193, Example 1194, Example 1195, Example 1196, Example 1197, Example 1198, Example 1199, Example 1200, Example 1201, Example 1202, Example 1203, Example 1204, Example 1205, Example 1206, Example 1207, Example 1208, Example 1209, Example 1210, Example 1211, Example 1212, Example 1213, Example 1214, Example 1215, Example 1216, Example 1217, Example 1218, Example 1219, Example 1220, Example 1221, Example 1222, Example 1223, Example 1224, Example 1225, Example 1226, Example 1227, Example 1228, Example 1229, Example 1230, Example 1231, Example 1232, Example 1233, Example 1234, Example 1235, Example 1236, Example 1237, Example 1238, Example 1239, Example 3301, Example 3302, Example 3303, Example 3304, Example 3305, Example 3306, Example 3307, Example 3308, Example 3309, Example 3310, Example 3311, Example 7001, Example 7002, Example 7003, Example 7004, Example 7005, Example 7006, Example 7007, Example 7008, Example 7009, Example 7010, Example 7011, Example 7012, Example 7013, Example 7014, Example 7015, Example 7016, Example 7017, Example 7018, Example 7019, Example 7020, Example 7021, Example 7022, Example 7023, Example 7024, Example 7025, Example 7026, Example 7027, Example 7028, Example 7029, Example 7030, Example 7031, Example 7032, Example 7033, Example 7034, Example 7035, Example 7036, Example 7037, Example 7038, Example 7039, Example 7040, Example 7041, Example 7042, Example 7043, Example 7044, Example 7045, Example 7046, Example 7047, Example 7048, Example 7049, Example 7050, Example 7051, Example 7052, Example 7053, Example 7054, Example 7055, Example 7056, Example 7057, Example 7058, Example 7059, Example 7060, Example 7061, Example 7062, Example 7063, Example 7064, Example 9001, Example 9002, Example 9003, Example 9004, Example 9005, Example 9006, Example 9007, Example 9008, Example 9009, Example 9010, Example 9011, Example 9012, Example 9013, Example 9014, Example 9015, Example 9016, Example 9017, Example 9018, Example 9019, Example 9020, Example 9021, Example 9022, Example 9023, Example 9024, Example 9025, Example 9026, Example 9027, Example 9028, Example 9029, Example 9030, Example 9031, Example 9032, Example 9033, Example 9034, Example 9035, Example 9036, Example 9037, Example 9038, Example 9039, Example 9040, Example 9041, Example 9042, Example 9043, Example 9044, Example 9045, Example 9046, Example 9047, Example 9048, Example 9049, Example 9050, Example 9051, Example 9052, Example 9053,

Example 9054, Example 9055, Example 9056, Example 9057, Example 9058, Example 9059, Example 9060, Example 9061, Example 9062, Example 9063, Example 9064, Example 9065, Example 9066, Example 9067, Example 9068, Example 9069, Example 9070, Example 9071, Example 9072, Example 9073, Example 9074, Example 9075, Example 9076, Example 9077, Example 9078, Example 9079, Example 9080, Example 9081, Example 9082, Example 9083, Example 9084, Example 9085, Example 9086, Example 9087, Example 9088, Example 9089, Example 9090, Example 9091, Example 9092, Example 9093, Example 9094, Example 9095, Example 9096, Example 9097, Example 9098, Example 9099, Example 9100, Example 9105, Example 9106, Example 9107, Example 9108, Example 9109, Example 9110, Example 9111, Example 9112, Example 9113, Example 9114, Example 10001, Example 10501, Example 10502, Example 10503, Example 10504, Example 10505, Example 10506, Example 10507, Example 10508, Example 10509, Example 10510, Example 10511, Example 10512, Example 10513, Example 10514, Example 10515, Example 10516, Example 10517, Example 13001, Example 13002, Example 13003, Example 13004, Example 13005, Example 13006, Example 13007, Example 13008, Example 13009, Example 13010, Example 13011, Example 13012, Example 13013, Example 13014, Example 14001, Example 14002, Example 14003, Example 14004, Example 14005, Example 14006, Example 14007, and Example 14008;
or a pharmaceutically acceptable salt thereof.

6. A compound of formula (II)



(II),

or a pharmaceutically acceptable salt thereof, wherein:

A is



;

wherein:

 denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;

n is 0 or 1;

R^{14} and R^{15} are independently selected from hydrogen and methyl; and

R^{16} is selected from hydrogen, $-CHR^{17}C(O)NH_2$, $-CHR^{17}C(O)NHCHR^{18}C(O)NH_2$, and $-CHR^{17}C(O)NHCHR^{18}C(O)NHCH_2C(O)NH_2$;

wherein R^{17} is selected from hydrogen and $-CH_2OH$ and wherein R^{18} is selected from hydrogen and methyl;

R^a, R^f, R^j, R^k, R^l, and R^m are hydrogen;

R^b and R^c are methyl;

R^g is methyl;

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, and R^{12} are independently selected from a natural amino acid side chain and an unnatural amino acid side chain or form a ring with the corresponding vicinal R group as described below;

R^d is methyl, or, R^d and R^4, together with the atoms to which they are attached selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halo, halomethyl, and hydroxy;;

R^e is selected from hydrogen and methyl, or, R^e and R^5, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, halomethyl, and hydroxy;

R^h is selected from hydrogen and methyl, or, R^h and R^8, together with the atoms to which they are attached, form a ring selected from azetidine, pyrollidine, morpholine,

piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, halomethyl, and hydroxy; and

R^i is methyl, or, R^i and R^9, together with the atoms to which they are attached selected from selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one or two groups independently selected from amino, cyano, methyl, halo, halomethyl, and hydroxy.

7. A compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein R^7 is phenylC_1-C_3alkyl optionally substituted with a fluoro group.

8. A compound selected from

Compound 71, Compound 72, Compound 73, Compound 74, Compound 75, Compound 76, Compound 77, Compound 78, Compound 79, Compound 80, Compound 81, Compound 82, Compound 83, Compound 84, Compound 85, Compound 86, Compound 87, Compound 89, Compound 90, Compound 95, Compound 96, Compound 97, Compound 98, Compound 1001, Example 3052, Example 3053, Example 3054, Example 3055, Example 3056-A, Example 3056-B, Example 3057, Example 3058-A, Example 3058-B, Example 3059, Example 3060-A, Example 3060-B, Example 3061, Example 3062, Example 3063, Example 3064, Example 3065, Example 3066, Example 3067, Example 3068, Example 3069, Example 3070, Example 3071, Example 3072, Example 3073, Example 3074, Example 3075, Example 3076, Example 3077, Example 3078, Example 3079, Example 3080, Example 3081, Example 3082, Example 3083, Example 3086, Example 3087, Example 3088, Example 3089, Example 3090, Example 3091, Example 3092, Example 3093, Example 3094, Example 3095, Example 3096, Example 3097, Example 3098, Example 3099, Example 3100, Example 3101, Example 3102, Example 3103, Example 3104, Example 3105, Example 3106, Example 3107, Example 3109, Example 3110, Example 3111, Example 3112, Example 3113, Example 3114, Example 3115, Example 3116, Example 3117, Example 3118, Example 3119, Example 3120, Example 3121, Example 3122, Example 3123, Example 3124, Example 3125, Example 3130, Example 3131, Example 3132, Example 3133, Example 3134, Example 3135, Example 3136, Example 3138, Example 3139, Example 3140, Example 3141, Example 3142, Example 3143, Example 3144, Example 3145, Example 3146, Example 3147, Example 3148, Example 3149, Example 3150, Example 3151, Example 3152, Example 3153, Example 3154, Example 3155,

Example 3156, Example 3157, Example 3158, Example 3159, Example 3160, Example 3161, Example 3162, Example 3163, Example 3164, Example 3165, Example 3166, Example 3167, Example 3168, Example 3171, Example 3172, Example 3173, Example 3174, Example 3175, Example 3176, Example 3177, Example 3178, Example 3179, Example 3180, Example 3181, Example 3182, Example 3183, Example 3184, Example 3185, Example 3186, Example 3187, Example 3188, Example 3189, Example 3190, Example 3191, Example 3192, Example 3193, Example 3194, Example 3195, Example 3196, Example 3197, Example 3198, Example 3199, Example 3200, Example 3201, Example 3202, Example 3203, Example 3204, Example 3205, Example 3206, Example 3207, Example 3208-A, Example 3208-B, Example 3209, Example 3500, Example 3501, Example 3502, Example 3503, Example 3504, Example 3505, Example 3506, Example 3507, Example 3508, Example 3509, Example 3510, Example 3511, Example 3512, Example 3513, Example 3514, Example 3515, Example 3516, Example 3517, Example 3518, Example 3519, Example 3520, Example 3522, Example 3523, Example 3524, Example 3525, Example 3526, Example 3527, Example 3528, Example 3529, Example 3531, Example 3532, Example 3533, Example 3534, Example 3535, Example 3536, Example 3537, Example 3538, Example 3539, Example 3540, Example 3541, Example 3542, Example 3543, Example 3544, Example 3545, Example 3546, Example 3547, Example 3548, Example 3549, Example 3550, Example 3551, Example 3552, Example 3553, Example 3555, Example 3556, Example 3557, Example 3558, Example 3559, Example 3560, Example 3561, Example 3562, Example 3563, Example 3564, Example 3565, Example 3566, Example 3567, Example 3568, Example 3569, Example 3570, Example 3571, Example 3572, Example 3573, Example 3574, Example 3575, Example 3576, Example 3577, Example 3578, Example 3579, Example 3580, Example 3581, Example 3582, Example 3583, Example 3584, Example 3585, Example 3586, Example 3588, Example 3589, Example 3590, Example 3591, Example 3592, Example 3593, Example 3594, Example 3595, Example 3596, Example 3597, Example 3598, Example 3599, Example 3600, Example 3601, Example 3602, Example 3603, Example 3604, Example 3605, Example 3606, Example 3607, Example 3608, Example 3609, Example 3610, Example 3611, Example 3613, Example 5001, Example 5002, Example 5003, Example 5004, Example 5005, Example 5006, Example 5007, Example 5008, Example 5009, Example 5010, Example 5011, Example 5012, Example 5013, Example 5014, Example 5015, Example 5016, Example 5017, Example 5018, Example 5019, Example 5020, Example 5021, Example 5022, Example 5023, Example 5024, Example 5025, Example 5026, Example 5027, Example 5028, Example 5029, Example 5030, Example 5031, Example 5032, Example 5033, Example 5034, Example 5035, Example

5036, Example 5037, Example 5038, Example 5039, Example 5040, Example 5041, Example 5042, Example 5043, Example 5044, Example 5045, Example 5046, Example 5047, Example 5048, Example 5049, Example 5050, Example 5051, Example 5052, Example 5053, Example 5054, Example 5055, Example 5056, Example 5057, Example 5058, Example 5059, Example 5060, Example 5061, Example 5062, Example 5063, Example 5064, Example 5065, Example 5066, Example 5067, Example 5068, Example 5069, Example 5070, Example 5071, Example 5072, Example 5073, Example 5074, Example 5075, Example 5076, Example 5077, Example 5078, Example 5079, Example 5080, Example 5081, Example 5082, Example 5083, Example 5084, Example 5085, Example 5086, Example 5087, Example 5088, Example 5089, Example 5090, Example 5091, Example 5092, Example 5093, Example 5094, Example 5095, Example 5096, Example 5097, Example 5098, Example 5099, Example 5100, Example 5101, Example 5102, Example 5103, Example 5104, Example 5105, Example 5106, Example 5107, Example 5108, Example 5109, Example 5110, Example 5111, Example 5112, Example 5113, Example 5114, Example 5115, Example 5116, Example 5117, Example 5118, Example 5119, Example 5120, Example 5121, Example 5122, Example 5123, Example 5124, Example 5125, Example 5126, Example 5127, Example 5128, Example 5129, Example 5130, Example 5131, Example 5132, Example 5133, Example 5134, Example 5135, Example 5137, Example 5138, Example 5139, Example 5141, Example 5142, Example 5143, Example 5144, Example 5145, Example 5146, Example 5147, Example 5140, Example 6001, Example 6002, Example 6003, Example 6004, Example 6005, Example 6006, Example 6007, Example 6008, Example 6009, Example 6010, Example 6011, Example 6012, Example 6013, Example 6014, Example 6015, Example 6016, Example 6017, Example 6018, Example 6019, Example 6020, Example 6021, Example 6022, Example 6023, Example 6024, Example 6025, Example 6026, Example 6027, Example 6028, Example 6029, Example 6030, Example 6031, Example 6032, Example 6033, Example 6034, Example 6035, Example 6036, Example 6037, Example 6038, Example 6039, Example 6040, Example 6041, Example 6042, Example 6043, Example 6044, Example 6045, Example 6046, Example 6047, Example 6048, Example 6049,and Example 6050;

or a pharmaceutically acceptable salt thereof.

9. A compound selected from

Compound 99, Compound 100, Compound 101, Compound 102, Compound 103, Compound 104, Compound 105, Compound 106, Compound 107, Compound 108,

Compound 109, Compound 110, Compound 111, Compound 112, Compound 113, Compound 114, Compound 115, Compound 116, Compound 117, and Compound 118; or a pharmaceutically acceptable salt thereof.

10. A compound having the formula as set out in Example 6046, or a pharmaceutically acceptable salt thereof.

11. The use of at least one compound selected from the compounds as claimed in claims 1 to 10 in the manufacture of a medicament for the treatment of autoimmune diseases that are associated with interferon gamma secretion in T-cells by enhancing, stimulating, and/or increasing the immune response in a subject in need thereof.

12. The use according to claim 11 wherein an additional agent is to be administered prior to, after, or simultaneously with said medicament .

13. The use according to claim 12 wherein the additional agent is an antimicrobial agent, an antiviral agent, a cytotoxic agent, and/or an immune response modifier.

14. The use of one or more compounds selected from the compounds as claimed in claims 1 to 10 in the manufacture of a medicament for the treatment of cancer by inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof.

15. The use according to claim 14 wherein the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, squamous cell carcinoma of the head and neck, carcinomas of the esophagus, gastrointestinal tract and breast, and a hematological malignancy.

16. The use of at least one compound selected from the compounds as claimed in claims 1 to 10 in the manufacture of a medicament for the treatment of an infectious disease that is associated with viral infection in a subject in need thereof.

17. The use according to claim 16 wherein the infectious disease is caused by a virus.

18. The use according to claim 17 wherein the virus is selected from HIV, Hepatitis A, Hepatitis B, Hepatitis C, herpes virus, and influenza.

19. The use of one or more compounds selected from the compounds as claimed in claims 1 to 10 in the manufacture of a medicament for the treatment of septic shock that is associated with viral infection in a subject in need thereof.

20. The use of at least one compound selected from the compounds as claimed in claims 1 to 10 in the manufacture of a medicament for the treatment of autoimmune diseases that are associated with interferon gamma secretion in T-cells by blocking the interaction of PD-L1 with PD-1 and/or CD80 in a subject.

21. The at least one compound selected from the compounds as claimed in claims 1 to 10 for use in therapy.

22. The at least one compound selected from the compounds as claimed in claims 1 to 10 for use as a medicament.